BR112022003862A2 - Tienopirimidonas como inibidores de trpa1 - Google Patents

Tienopirimidonas como inibidores de trpa1

Info

Publication number
BR112022003862A2
BR112022003862A2 BR112022003862A BR112022003862A BR112022003862A2 BR 112022003862 A2 BR112022003862 A2 BR 112022003862A2 BR 112022003862 A BR112022003862 A BR 112022003862A BR 112022003862 A BR112022003862 A BR 112022003862A BR 112022003862 A2 BR112022003862 A2 BR 112022003862A2
Authority
BR
Brazil
Prior art keywords
thienopyrimidones
inhibitors
trpa1
trpa1 inhibitors
same
Prior art date
Application number
BR112022003862A
Other languages
English (en)
Inventor
Thomas Fleck Martin
Paul Christian Binder Florian
Dahmann Georg
P Hehn Joerg
Charlotte Heimann Annekatrin
Willwacher Jens
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112022003862A2 publication Critical patent/BR112022003862A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

TIENOPIRIMIDONAS COMO INIBIDORES DE TRPA1. A presente invenção refere-se a tienopirimidinonas e seu uso como inibidores da atividade de TRPA1, composições farmacêuticas que contêm as mesmas e métodos de uso das mesmas como agentes para tratamento e/ou prevenção de doenças fibróticas, doenças inflamatórias e autoimunes e doenças relacionadas ao SNC.
BR112022003862A 2019-10-15 2020-10-14 Tienopirimidonas como inibidores de trpa1 BR112022003862A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203171 2019-10-15
PCT/EP2020/078853 WO2021074196A1 (en) 2019-10-15 2020-10-14 Thienopyrimidones as trpa1 inhibitors

Publications (1)

Publication Number Publication Date
BR112022003862A2 true BR112022003862A2 (pt) 2022-08-23

Family

ID=68289872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003862A BR112022003862A2 (pt) 2019-10-15 2020-10-14 Tienopirimidonas como inibidores de trpa1

Country Status (13)

Country Link
US (1) US11136336B2 (pt)
EP (1) EP4045509A1 (pt)
JP (1) JP7376706B2 (pt)
KR (1) KR20220083778A (pt)
CN (1) CN114929712A (pt)
AU (1) AU2020366553A1 (pt)
BR (1) BR112022003862A2 (pt)
CA (1) CA3153618A1 (pt)
CL (1) CL2022000758A1 (pt)
IL (1) IL292093A (pt)
MX (1) MX2022004565A (pt)
TW (1) TW202132309A (pt)
WO (1) WO2021074196A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140234A1 (es) * 2010-12-20 2014-03-08 Glenmark Phamaceuticals S A Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
BR112013032025A2 (pt) * 2011-06-13 2016-12-20 Glenmark Pharmaceutical S A antagonistas trpa1, compostos ou seus sais farmaceuticamente aceitáveis, métodos para reduzir a quantidade de eosinófilos ou neutrófilos e/ou aumentar fev1 em indivíduo com distúrbio respiratório, para tratar distúrbio respiratório em indivíduo e/ou para identificar antagonista trpa1, usos de quantidade eficaz de antagonista trpa1, e composição farmacêutica para administração por inalação
EP3180345B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
CN105335639A (zh) * 2014-08-15 2016-02-17 中兴通讯股份有限公司 一种电子设备中功能锁的实现方法和装置
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Also Published As

Publication number Publication date
AU2020366553A1 (en) 2022-03-31
CL2022000758A1 (es) 2023-01-20
KR20220083778A (ko) 2022-06-20
US20210107918A1 (en) 2021-04-15
JP2022551712A (ja) 2022-12-13
MX2022004565A (es) 2022-05-06
IL292093A (en) 2022-06-01
TW202132309A (zh) 2021-09-01
WO2021074196A1 (en) 2021-04-22
EP4045509A1 (en) 2022-08-24
CA3153618A1 (en) 2021-04-22
CN114929712A (zh) 2022-08-19
JP7376706B2 (ja) 2023-11-08
US11136336B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
BR112022011917A2 (pt) Fluoroalquil-oxadiazois e seus usos
SV2018005787A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112015022462A2 (pt) inibidores de ido
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
BR112015032595A2 (pt) inibidores de ido
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
BR112022001415A2 (pt) Agentes interleucina-2 e os usos dos mesmos
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
BR112022010082A2 (pt) Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
BR112017018198A2 (pt) inibição da atividade de olig2
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MA40406A (fr) Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
EA201790282A1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофил-эластазы

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]